As a result, PD-L1 expression in solid tumor biopsies, including primary liver cancer, has been used to predict the efficacy (in terms of improved survival) of anti-PD-1 or anti-PD-L1 therapy [62]. The gene discussed is CD274; the disease is liver cancer.